Nasdaq: CNTB/Biotechnology
Connect Biopharma Holdings Limited
San Diego, CA, United States
Company overview
Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD). The company was founded in 2012 and is headquartered in San Diego, California.
This profile is for informational purposes only and is not investment advice. Company information may change after the verification date.